This week in drug discovery (20-24 May) 

News round-up for 20-24 May by DDW Senior Digital Content Editor Diana Spencer.

The headline news this week emphasises the importance of shared expertise and collaboration, whether that be between nations, companies or research institutions, to enable the greatest advances in drug discovery.

The top stories:

Partners explore precision medicine approach to heart disease

PlaqueTec and the Welch research group at the Babraham Institute have announced the completion of their collaboration to evaluate lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec.

AI collaboration shows success for novel heart failure target

AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI.

Peptide shows promise as therapeutic for bone loss disorders

Researchers have shown that a naturally occurring peptide holds promise as a new therapeutic for bone loss disorders and could have advantages over existing drugs.

Could a modified cold sore virus cure brain cancer?

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children.

Autoimmune mRNA therapeutics research collaboration

etherna has entered a research collaboration with Hasselt University (UHasselt) to develop an mRNA based treatment for autoimmune disorders.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free